Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1

Neoplasia

Volumn 12, Issue 3, 2010, Pages 244-253

  Tennis, Meredith A ^a   Van Scoyk, Michelle ^a   Heasley, Lynn E ^a   Vandervest, Katherine ^a   Weiser Evans, Mary ^a   Freeman, Scott ^a   Keith, Robert L ^a,b   Simpson, Pete ^a   Nemenoff, Raphael A ^a   Winn, Robert A ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; CELL SURFACE RECEPTOR; CIGLITAZONE; FRIZZLED 9 PROTEIN; FRIZZLED PROTEIN; ICOSANOID; ILOPROST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN E2; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG; WNT PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77949577467     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91690     Document Type: Article

References (40)

1. Michaud CM, Murray CJ, and Bloom BR (2001). Burden of disease - implications for future research. JAMA 285, 535-539.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008). Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, and Thun MJ (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
4. Honn KV, Cicone B, and Skoff A (1981). Prostacyclin: a potent antimetastatic agent. Science 212, 1270-1272.
5. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, and Geraci MW (2002). Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res 62, 734-740.
6. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, and Geraci MW (2004). Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res 64, 5897-5904.
7. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, et al. (2008). Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator-activated receptor gamma. Cancer Prev Res (Phila Pa) 1, 349-356.
8. Narumiya S, Sugimoto Y, and Ushikubi F (1999). Prostanoid receptors: structures, properties, and functions. Physiol Rev 79, 1193-1226.
9. Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, Heasley LE, and Nemenoff RA (2006). Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor γ. J Biol Chem 281, 26943-26950.
10. Bren-Mattison Y, Van Putten V, Chan D, Winn R, Geraci MW, and Nemenoff RA (2005). Peroxisome proliferator-activated receptor-γ (PPARγ) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene 24, 1412-1422.
11. Wick M, Hurteau G, Dessev C, Chan D, Geraci MW, Winn RA, Heasley LE, and Nemenoff RA (2002). Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase- independent inhibition of lung cancer cell growth. Mol Pharmacol 62, 1207-1214.
12. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, et al. (2005). Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J Biol Chem 280, 19625-19634.
13. Winn RA, Bremnes RM, Bemis L, Franklin WA, Miller YE, Cool C, and Heasley LE (2002). γ-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 21, 7497-7506.
14. Hubbard WC, Alley MC, Gray GN, Green KC, McLemore TL, and Boyd MR (1989). Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res 49, 826-832.
15. Kreutzer M, Fauti T, Kaddatz K, Seifart C, Neubauer A, Schweer H, Komhoff M, Muller-Brusselbach S, and Muller R (2007). Specific components of prostanoid-signaling pathways are present in non-small cell lung cancer cells. Oncol Rep 18, 497-501.
16. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, et al. (2005). Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol 167, 1763-1775.
17. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, and Narumiya S (1997). Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122, 217-224.
18. Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, and DuBois RN (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 97, 13275-13280.
19. Keshamouni VG, Reddy RC, Arenberg DA, Joel B, Thannickal VJ, Kalemkerian GP, and Standiford TJ (2004). Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer. Oncogene 23, 100-108.
20. Kawano Y and Kypta R (2003). Secreted antagonists of the Wnt signalling pathway. J Cell Sci 116, 2627-2634.
21. Claria J (2003). Cyclooxygenase-2 biology. Curr Pharm Des 9, 2177-2190.
22. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, and DuBois RN (2005). Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23, 254-266.
23. Tapiero H, Ba GN, Couvreur P, and Tew KD (2002). Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother 56, 215-222.
24. Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, and Massion PP (2008). Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol 39, 689-696.
25. Katanaev VL, Ponzielli R, Semeriva M, and Tomlinson A (2005). Trimeric G protein-dependent frizzled signaling in Drosophila. Cell 120, 111-122.
26. Malbon CC (2004). Frizzleds: new members of the superfamily of G-protein-coupled receptors. Front Biosci 9, 1048-1058.
27. Wang HY, Liu T, and Malbon CC (2006). Structure-function analysis of Frizzleds. Cell Signal 18, 934-941.
28. Wang HY and Malbon CC (2004). Wnt-frizzled signaling to G-protein-coupled effectors. Cell Mol Life Sci 61, 69-75.
29. Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, Okamura H, Woodgett J, and He X (2005). A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438, 873-877.
30. Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, and Clapp LH (2007). IP receptor-dependent activation of PPARγ by stable prostacyclin analogues. Biochem Biophys Res Commun 360, 821-827.
31. Keshamouni VG, Arenberg DA, Reddy RC, Newstead MJ, Anthwal S, and Standiford TJ (2005). PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 7, 294-301.
32. Reddy RC, Srirangam A, Reddy K, Chen J, Gangireddy S, Kalemkerian GP, Standiford TJ, and Keshamouni VG (2008). Chemotherapeutic drugs induce PPAR-γ expression and show sequence-specific synergy with PPAR-γ ligands in inhibition of non-small cell lung cancer. Neoplasia 10, 597-603.
33. Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, and Lang NP (2007). Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 25, 1476-1481.
34. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, and Beuschlein F (2005). Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 90, 3886-3896.
35. Chang TH and Szabo E (2000). Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 60, 1129-1138.
36. Han S, Rivera HN, and Roman J (2005). Peroxisome proliferator-activated receptor-γ ligands inhibit α5 integrin gene transcription in non-small cell lung carcinoma cells. Am J Respir Cell Mol Biol 32, 350-359.
37. Han S, Sidell N, Fisher PB, and Roman J (2004). Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor γ in human lung carcinoma cells. Clin Cancer Res 10, 1911-1919.
38. Seargent JM, Yates EA, and Gill JH (2004). GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br J Pharmacol 143, 933-937.
39. Takekawa M, Maeda T, and Saito H (1998). Protein phosphatase 2Ca inhibits the human stress-responsive p38 and JNK MAPK pathways. EMBO J 17, 4744-4752.
40. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, Hla T, and Kondo M (2000). Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-γ agonists through induction of apoptosis. Biochem Biophys Res Commun 270, 400-405.